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ABSTRACT 
Background: Venous thromboembolism (VTE) is the third most common cardiovascular 
disease with a high recurrence rate. There is a risk of chronic complications affecting health-
related quality-of life (QoL).     
Aim: To evaluate long-term consequences of VTE in women and to study and to explore the 
risk factors for recurrent event, arterial cardiovascular disease (CVD), mortality, post-
thrombotic syndrome (PTS) and QoL. 
Methods: We performed a cohort study inviting 1433 women with a previous episode of VTE 
(exposed) and 1402 women without VTE (unexposed). The cohort was derived from the 
‘Thrombo Embolism Hormone Study’ (TEHS), a Swedish nation-wide case-control study on 
risk factors for VTE, recruiting women 2002 - 2009. During 2011 all women were followed up 
through a mailed questionnaire, including questions on life-style factors, recurrent VTE and 
inquiries according to the QoL instrument SF-36. To assess disease specific QoL, exposed 
women were also asked questions according to VEINES-Sym / VEINES-QoL. A modified 
Villalta scale was applied to evaluated PTS. Information on CVD and mortality was obtained 
through the Patient Register and the Cause of Death Register. Baseline data on life style factors, 
risk factors for VTE, including hormone treatment and family history of VTE and CVD were 
collected through a telephone interview within three months after the diagnosis of VTE for the 
exposed, or at time of inclusion in TEHS for unexposed. Blood samples for DNA-analyses 
were collected at time of inclusion in TEHS. 
Result: A total of 2117 women (1087 (75%) exposed and 1030 (73%) unexposed) accepted 
participation in the study. During a median follow-up of 5 years (range 0.1-9.1), 10 % of 
exposed women had a recurrent event. The risk of recurrence was highest among women with 
unprovoked VTE and obesity. Women with hormone-induced VTE had a lower risk of 
recurrence than women with unprovoked VTE but not as low as women with surgery/cast 
induced VTE. Women carrying the risk alleles of F5 rs6025/Factor V Leiden (FVL) and F11 
rs2289252 had a significantly higher risk of recurrence compared to non-carriers (HR 1.7 (95% 
CI 1.1-2.6) and 1.8 (95% CI 1.1-3.0) respectively). In a subgroup analysis of women with 
unprovoked VTE the difference was even larger, with a cumulative recurrence rate of 21.9% 
(95% CI 13.7-34.0) versus 7.5 % (95% CI 3.4-16.0) for non-carriers at 5 years follow-up. The 
mortality rate for exposed women was 5.7 /1000 person years with the corresponding mortality 
rate for unexposed of 2.2 /1000 person years, generating a HR of 2.4 (95% CI 1.2-4.6). None 
of the exposed died from VTE. During follow-up 35 (3.2%, 95% CI 2.1-4.3) among the 
exposed and 14 (1.4%, 95% CI 0.7–2.1) among the unexposed had any CVD event. Women 
with unprovoked VTE and pulmonary embolism had the highest risk of both death and CVD. 
The prevalence of self-reported PTS among all exposed was 20 % (95% CI 18-22). Women 
with proximal deep vein thrombosis had the highest prevalence (30%, 95% CI 25-35). Women 
reporting PTS had significantly lower QoL compared to both unexposed women and exposed 
women without PTS. Other factors affecting QoL were obesity, physical inactivity and 
recurrent VTE.  
Conclusion: Among young and middle-aged women, the overall recurrence rate of VTE was 
low, indicating that the majority may not benefit from prolonged anticoagulation after a first 
episode of VTE. A combination of FVL and F11 rs2289252 may be useful to predict the risk 
of recurrence. PTS, the most common complication, was seriously affecting QoL. Women with 
prior VTE had a two-fold increased risk of both overall mortality and CVD compared to 
unexposed. Obesity was a shared risk factor for recurrent VTE, PTS and reduced QoL.   
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1 INTRODUCTION 
Annually, in Europe, there will be about one million events of venous thromboembolism 
(VTE), defined as deep vein thrombosis and pulmonary embolism. About four to five hundred 
thousand will die from pulmonary embolism every year. Among survivors of pulmonary 
embolism two to four in every 100 patients will develop chronic thromboembolism pulmonary 
hypertension. Up to half of patients suffering a deep vein thrombosis will develop post-
thrombotic syndrome, a chronic, burdensome complication seriously affecting health related 
quality of life. There is also a risk of recurrent VTE, with a cumulative recurrence rate of about 
30-40 % over 10 years. VTE is a disease with a complex pathophysiology including both 
genetic and acquired risk factors. VTE is an important health issue in women with surgery, 
pregnancy and postmenopausal hormone therapy as important risk factors. One of the most 
frequent acquired risk factor of VTE among women in childbearing age is the use of oral 
contraceptives.  
The ‘Thrombo Embolism Hormone Study’ (TEHS) started in 2002 in Sweden and was 
designed to evaluate risk factors for VTE in women. About two years later I was involved in 
the project including patients at Södersjukhuset in Stockholm. During the following years I 
was a part of the formation of the TEHS-follow-up study. Throughout the process I have 
learned a lot. My major learning outcome was to be introduced to epidemiological research and 
to understand how much time and effort that is needed to complete a project like this. 
The focus of this thesis was to gain better knowledge on the consequences of VTE in young 
and middle aged women. 
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2 BACKGROUND 
2.1 VENOUS THROMBOEMBOLISM 
2.1.1 Epidemiology 
Venous thromboembolism (VTE) is a common disease with an overall incidence of 1-2/1000 
person years (1, 2). The incidence is increasing with age for both men and women with a 
slightly higher overall age adjusted incidence rate for men. In contrast, the incidence for women 
is somewhat higher during childbearing age, probably due to the use of estrogen containing 
contraceptives and pregnancy (3, 4). After a first episode of VTE about 25 % will suffer a 
recurrent event within five years (5, 6). Approximately 30-50 % of persons suffering a deep 
vein thrombosis (DVT) will develop post-thrombotic syndrome (PTS) and up to 5 % of patients 
with pulmonary embolism (PE) will suffer from chronic thromboembolic pulmonary 
hypertension (CTEPH) (7-9). PTS and CTEPH both seriously affecting health related quality 
of life (QoL) (10, 11). 
2.1.2 Etiology  
Already in the middle of the 19th century Rudolph Virchow proposed three main causes of 
VTE; stasis of the blood, changes in the vessel wall and changes in the composition of the 
blood (12). It is still valid that VTE is a multifactorial disease with both genetic and acquired 
risk factors, not seldom interacting within one patient (1, 13). Acquired risk factors for VTE 
includes age, trauma, surgery, estrogen, pregnancy, malignancy and a number of medical or 
inflammatory illnesses (14, 15). The strongest acquired risk factors for VTE are surgery and 
active cancer. Without prophylaxis with anticoagulants about 40-60 % of patients undergoing 
major orthopedic surgery in the lower limb will suffer from a VTE (16). Women using 
contraceptives containing estrogen have a 2 to 4 fold increased risk of VTE compared to non-
users (17).  
A number of inherited thrombophilias associated with an increased risk of VTE have been 
described (1, 18, 19). First the deficiency of the inhibitors of the natural anticoagulants, 
antithrombin, Protein S and Protein C were described, being rare but strongly associated with 
risk of VTE (20). The later described, and most common thrombophilias are the FV Leiden, 
F5 rs6025 mutation (FVL) and the prothrombin G20210A, F2 rs1799963 mutation (F2 
(G20210A)) (19, 21). These thrombophilias increase the risk of VTE about 5 to 2 fold 
respectively, when appearing in heterozygous forms (22-24).  
2.1.3 Clinical Features and Treatment 
Diagnosis 
The most common location of VTE is deep vein thrombosis (DVT) in the lower limb or 
pulmonary embolism (PE). DVT in the lower limb is divided into distal DVT, involving the 
calf veins and proximal DVT involving the popliteal vein and veins more proximal.   
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Since the clinical diagnosis of VTE is unreliable the diagnosis has to be confirmed by an 
objective test. The most commonly used diagnostic approach is a combination of clinical 
probability, D-dimer testing and objective radiological tests. Wells score is a widely used 
clinical pretest probability instrument, classifying patients into high and low risk groups (25). 
Patients with a high pretest probability of DVT is usually further examined by Doppler 
ultrasonography or, more seldom, venography (26). For patients with suspicion of PE the most 
frequently used objective test is computed tomography (CT) scan, followed by ventilation-
perfusion scan for patients having contraindications for CT (27).  
 
Treatment  
Treatment of VTE is started with parenteral, subcutaneous, injections of low molecular weight 
heparin (LMWH), usually already at time of clinical suspicion of VTE, awaiting the result of 
the objective test. Once VTE is confirmed, treatment with anticoagulation therapy is continued, 
either by initiation of any of the new oral anticoagulants (NOAC) or vitamin K antagonist 
(VKA) while continuation of LMWH until international normalized ratio (INR) is 2.0 – 3.0. 
Treatment should be continued for at least three months to avoid early recurrence. For patients 
considered having a high risk of recurrence, anticoagulant treatment should be extended (28, 
29).   
Reproduced with permission from Tapson, VF N Engl J Med 2008; 358:1037-1052, 
Copyright Massachusetts Medical Society. 
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2.2 CONSEQUENCES OF VTE 
2.2.1 Recurrent VTE 
Within 5 years after a first episode of VTE about 20-25 % of patients will suffer from a 
recurrent event (30-32). The risk of recurrence is effectively prevented by continuing 
anticoagulant treatment, although at a prize of an increased risk of major bleeding (33, 34). 
Therefore, one of the most challenging clinical issues is to identify patients having a high risk 
of recurrent events who therefore will gain from prolonged anticoagulation. Many of the risk 
factors associated with first episode of VTE do not affect or even reduce the risk of recurrent 
events. The risk of recurrence is lower when the first episode of VTE was provoked by a 
transient risk factor like surgery (35-37). Presence of heterozygous FVL or F2 (G20210A) only 
slightly, if at all, increases the risk of recurrent VTE (38). It is known that women have a lower 
risk of recurrence than men but the reason for this is so far not fully known (5, 39-41). Previous 
studies on the risk of recurrence after a hormone related VTE are conflicting. Some studies find 
similar risk for unprovoked and hormone related VTE (42, 43), whereas others find reduced 
risk of recurrence after VTE related to hormones (39, 44).  
Patients with an unprovoked VTE have the highest risk of recurrence. There are some clinical 
scoring algorithms derived to help identifying patients with unprovoked VTE being at low risk 
of recurrence, who safely can stop anticoagulation therapy. In the ‘Men continue and 
HERDOO2 rule’ no men with idiopathic VTE and only women with no more than one risk 
factor (age above 65, obesity and increased D-dimer) fall into the low risk group who safely 
can stop anticoagulation (45). In the Vienna prediction model D-dimer, male sex and location 
of first VTE (PE and proximal DVT versus distal DVT) are associated with a higher risk of 
recurrence (46). In the DASH prediction model risk factors associated with an increased risk 
of recurrence are male sex, persistently increased D-dimer after anticoagulation is stopped, age 
below 50 years and in women VTE not associated with hormonal treatment (47).  
None of the prediction models above contains any genetic markers. Nevertheless, previous 
studies have found that the heritability of VTE is strong (48-50). Family history of VTE has 
been found to be a risk factor for first VTE, even in the absence of the known thrombophilias 
(51, 52). Heritability has also been found to be a predictor of hospitalization for recurrent VTE 
in a Swedish study (53). The effect of heritability was strongest in younger patients, suggesting 
a genetic contribution. However, screening for the known thrombophilias has not been found 
to be of clinical relevance to predict recurrence, suggesting other genetic variants to be present 
(54).  
2.2.2 Cardiovascular disease 
Arterial cardiovascular disease (CVD) and VTE have traditionally been regarded as two 
different diseases. VTE usually arises in vessels with low blood flow and shear stress and the 
clot consists mostly of erythrocytes and fibrin. Arterial thrombi on the other hand develop in 
vessels with high shear stress and are predominantly platelet-rich (55, 56). However, since 
2003 when Prandoni et al (57) reported a higher incidence of atherosclerotic plaque in patients 
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with unprovoked VTE there are more studies confirming the relationship between VTE and 
CVD (58-61). Patients hospitalized for CVD have been found to have an increased risk of 
subsequent VTE in one large register-based Danish study (61). However other studies found 
no association between VTE and CVD, or the association disappeared after adjustment for 
potential confounders (62, 63). Furthermore, patients with VTE seem to have an increased risk 
of subsequent CVD (60, 64, 65). Whether the relationship between VTE and CVD is explained 
by common risk factors or a causal link is still unclear (66, 67). If the association was explained 
by common risk factors the correlation would diminish or disappear after adjustment. In some 
studies, adjustment was not possible (60) but in other studies adjustment for common risk 
factors only modestly changed the risk estimates (68-70) suggesting common risk factors is not 
the full explanation.  
2.2.3 Malignancy 
For more than a hundred years ago Armand Trousseau first described the association between 
cancer and VTE (71). Hereafter, a large number of studies have found not only that patients 
with known malignancy have an increased risk of VTE (72-74) but also that patients with VTE 
have an increased risk of developing subsequent cancer (58, 74, 75). Among patients who 
become ill in symptomatic DVT about 20 % are diagnosed with an active cancer (15, 76). 
However, VTE might also be the first sign of undiagnosed cancer. Cohort studies of patients 
with VTE report that 6-13% of patients have been diagnosed with a new cancer four to nine 
years after an episode of VTE (58, 75).  One meta-analysis found a 3-fold increased risk of 
occult malignancy in patients with VTE compared to patients without VTE (76). The risk was 
highest for patients with unprovoked VTE.   
2.2.4 Mortality 
It has been found that overall mortality is increased after VTE, especially after PE (58, 77, 78). 
Mortality is highest in the first year after a VTE-event and mortality rates of 20-25 % within 
one year have been reported (32, 79). For patients with PE early death is due to direct 
hemodynamic effects of PE, although studies report increased mortality even beyond the acute 
period. Mortality is then usually due to concomitant disease, most commonly malignant disease 
(32, 58, 80-83). However, even in studies including VTE-patients without malignancy, 
mortality is increased (32, 78). Results on whether the long-term survival after a VTE event 
differs from the general population are not consistent (32, 80-82). 
2.2.5 Health Related Quality-of-life 
While epidemiology, etiology and treatment of VTE have been described in many studies, there 
are only a few studies investigating how QoL is affected by VTE. Not until late 1980s and early 
1990s assessing QoL became a focus of interest in health science. Now, more and more clinical 
trials include QoL as an important endpoint (84). When measuring QoL it is important to use 
both generic and disease-specific instruments (85, 86). Generic instruments are needed for 
comparisons between various patient groups and between studies, while disease-specific 
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instrument usually are better to evaluate changes over time and treatment effects in patients 
with the same disease (86, 87).  
Previous studies assessing QoL after VTE report that VTE-patients score significantly lower 
on both mental and physical health status measured with 36- Item Short-Form Health Survey 
(SF-36). Prevalence of PTS was the predominant predictor of low QoL after DVT (10, 88-90).  
2.2.6 Post-thrombotic syndrome  
PTS is one of the most common complications of DVT.  PTS is a chronic condition that 
develops in 20–50% of patients within 1–2 years after an episode of symptomatic DVT in the 
lower limbs (8, 58, 91, 92). Some studies have also found PTS after an asymptomatic DVT 
(93, 94). PTS is characterized by symptoms such as pain, swelling, heaviness, cramping and 
objective signs such as edema, hyperpigmentation and varicose veins. PTS is burdensome to 
patients as well as expensive, both in terms of direct medical costs and indirect costs such as 
loss of productivity (95). Women seem to be more prone to develop PTS (96). Important risk 
factors for PTS appear to be ipsilateral recurrence of DVT, poor quality of initial anti-
coagulation for the treatment of DVT and increased body mass index (BMI) (7, 97, 98).  
Diagnosis 
PTS is a clinical diagnosis with no single gold standard test. There are a number of clinical 
tools to diagnose PTS. In order to standardize the definition of PTS ‘The International Society 
of Thrombosis and Haemostasis’ (ISTH) has recommended the use of the Villalta scale (99). 
The Villalta scale comprises of five patient-rated symptoms and six clinical-rated signs (Table 
1).  
Table 1. The Villalta Scale 
Symptoms Signs 
Pain Pretibial edema 
Cramps Skin induration 
Heaviness Hyperpigmentation 
Paresthesia Redness 
Itching Venous ectasia 
 Pain on calf compression 
All symptoms and signs score from 0 (absent) to 3 (severe). PTS is considered present if 
score ≥ 5 and severe if ≥ 15 or the presence of a venous ulcer.  
Adapted from Prandoni, Villalta et al Haematologica 1997 
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Pathophysiology 
The pathogenesis of PTS is not fully understood. Venous hypertension seem to play an 
important role, but whether PTS depends on outflow obstruction, venous valvular reflux or 
both is not consistent (97). Previous studies report higher incidence of PTS in patients with 
persistent venous obstruction suggesting outflow obstruction is a risk factor for PTS (100-102). 
In a clinical study, the Catheter-Directed Venous Thrombolysis Trial (CaVenT), comparing 
catheter-directed thrombolysis (CDT) to standard treatment with anticoagulants and 
compression stockings, the risk of PTS was reduced in the group of patients treated with CDT. 
Compared to patients receiving conventional anticoagulant treatment more patients receiving 
CDT had ileofemoral patency, but there was no difference between the groups regarding 
valvular reflux (97, 98, 103). PTS might also be due to damage in the vessel wall and both 
acute and chronic inflammation might be drivers of PTS (104, 105).  
Treatment 
Previously the most used prevention and treatment strategy for PTS has been the use of elastic 
compression stockings (ECS). However, since Kahn et al presented a randomized controlled 
trial, the SOX-trial (106), showing no effect on PTS using ECS the use of stockings has been 
questioned. Hence, there are very few side effects of ESC and it can be used to reduce 
symptomatic swelling. Though based on sparse data, physical activity might benefit some 
patients with PTS (97).   
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3 AIMS 
VTE is a common condition associated with high risk of recurrence, increased mortality and 
risk of PTS as a chronic complication. It also affects health-related quality-of-life.  
The overall objectives of this thesis were to investigate long term consequences after a first 
episode of venous thromboembolism in women 18-64 years of age.  
The specific aims of the studies were: 
• To study the risk of recurrence after a first episode of VTE and to assess the risk related 
to unprovoked VTE and VTE provoked by surgery/cast or hormonal treatment. 
 
• To investigaste if a genetic risk score previously found to predict a first episode of VTE 
could be used to predict recurrent VTE. 
 
• To assess the risk of CVD and mortality after a first episode of VTE compared to a 
control group and futher to assess risk factors for CVD and mortality in women with 
VTE. 
 
• To examine how QoL is affected after a first episode of VTE compared to a control 
group and to assess risk factors for low QoL after a first time VTE. Futhermore, to 
investigare the incidence of, and risk factors for, PTS after a first episode of VTE.  
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4 MATERIAL AND METHODS 
4.1 STUDY DESIGN AND STUDY POPULATION 
We conducted a long-term prospective follow-up of a cohort of women exposed to a first 
episode of VTE and age-matched controls. The cohort was derived from the ‘Thrombo 
Embolism Hormone Study’ (TEHS). In the follow-up study women with a previous VTE were 
included as exposed and women serving as controls in TEHS were considered unexposed. 
4.1.1 TEHS 
TEHS is a population-based case-control study initiated by the Swedish Medical Products 
Agency in collaboration with Karolinska Institutet and the Royal Institute of Technology. 
TEHS was designed to investigate genetic and environmental risk factors for VTE in women 
18-64 years of age. The study has been well described by Bergendal et al (107). A total of 1433 
women with a first episode of DVT of the lower limb or a PE were included as cases at 43 
hospitals distributed all over Sweden (Figure 1). In hospitals with a centralized management of 
VTE (n= 32) women were identified by a study coordinator at the department. In hospitals 
without a centralized management (n=11) potential study participant were identified through 
the Department of Radiology and the Department of Clinical Physiology. A copy of the 
radiology report was sent to the coordinating center. To make sure that it was acceptable to 
contact the women a research nurse contacted the clinician responsible for the potential case.  
 
Figure 1 Flow-chart of inclusion in the 'Thrombo Embolism Hormone Study' 
The VTE event had to be objectively verified by phlebography or color Doppler 
ultrasonography for women with DVT. For women with PE the diagnosis was verified by CT 
scan of the pulmonary arteries, pulmonary angiography or by perfusion and ventilation 
scintigraphy. Only cases initiating anticoagulant treatment were considered having a 
symptomatic VTE and were included in the study as such. 
Cases 
n=1630
From 43 hospitals 
in Sweden
Controls
n=2305
From Swedish 
Population Register
Rejected or 
restrained 
participation
n=160
Interview and 
blood sample
n=1470
Rejected or 
restrained 
participation
n=715
Interview and 
blood sample
n=1590
Incomplete 
interview 
or 
no signed consent 
n=37
Incomplete 
interview 
or 
no signed consent 
n=188
Final analysis
n=1433
Final analysis
n=1402
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Controls were randomly selected from the Swedish population registry and matched to cases 
according to age. All participants were recruited prospectively in Sweden from 2002 to January 
2009. During 2002 recruitment of patients and controls started in a pilot study and in 2003 the 
main study of TEHS started to recruit both patients and controls. Women with a previously 
diagnosed VTE event, pregnancy during the last three months or current, or a history of 
malignancy within the past five years were excluded.  
All cases and controls were interviewed through a telephone call by a specially trained research 
nurse using a structured questionnaire to obtain information on acquired risk factors for VTE 
and baseline characteristics. Because the interview was in Swedish, non-Swedish speaking 
women were not eligible for the study. At time of inclusion in the study all women donated 5 
mL of whole blood. DNA was prepared using QIAGEN FlexiGene DNA-kit.  
4.1.2 TEHS-follow-up 
In 2011 all women included in TEHS, still living in Sweden, were asked to participate in TEHS-
follow-up by a questionnaire sent by mail (Figure 2). If the questionnaire was not returned 
within one month a reminder was sent. During the follow-up period 38 out of the 1433 women 
with previous VTE deceased. One women answered the questionnaire and died six months 
after. Among the 1402 without VTE at inclusion in TEHS, 12 deseased during follow-up.  
 
 
Figure 2 Flow-chart of the study cohort of TEHS-follow-up.  
The questionnaire covered different medical aspects, such as current medication, duration of 
previous and current anticoagulant treatment, hormone therapy with combined hormonal 
contraceptive (CHC) or menopausal hormonal treatment (HT), recurrent events of VTE and 
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CVD. There were also questions regarding life style factors such as weight, smoking and 
physical activity. To assess QoL the questionnair included questions according to SF-36 for all 
women and VEINES-QoL/VEINES-Sym for women exposed to a previous VTE. For exposed 
women the questionnaire also included questions according to a self reported Villalta scale, 
modified to suit questionnaire (8).  
Information on CVD, mortality and malignancy were obtained from the Swedish Patient 
Register, The Cause of Death Register and the Cancer Register held by the National Board of 
Health and Welfare. 
 
Figure 3 shows information on the selected study populations of the TEHS follow-up cohort 
included in the 4 papers. A short summary is listed below. 
 
Figure 3 Flow-chart of the study cohort of TEHS-follow-up, divided by the papers included 
in the thesis. 
Paper I included women (n=974) with a previous VTE alive at time of follow-up. Women on 
anticoagulant treatment (n=53) or missing information on anticoagulant treatment (n=22) were 
not eligiable since they were not considered being at risk of recurrent VTE.   
 
In paper II both women being alive at time of follow-up as well as women who deceased during 
follow-up (n=1010)  with a previous VTE  were included in the analysis.  
 
Paper III included 1081 exposed women, of whom 1044 were alive, and 1027 unexposed 
women, of whom 1016 were alive. Women with CVD prior to inclusion in TEHS (n=9) were 
excluded.   
 
In paper IV 1040 exposed and 994 unexposed alive women with complete questionnaire 
regarding the QoL-instruments were included.  
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4.2 DATA COLLECTION 
4.2.1 TEHS 
Baseline information was collected through a telephone interview within three months of the 
VTE-event for exposed women and at time of interview for unexposed. Data included 
questions on acquired risk factors including detailed information on hormonal intake and 
information on surgery and/or plaster cast. The interview contained questions on life-style 
factors such as weight, height, smoking and physical activity. The study participants were also 
asked about leg symptoms (pain, heaviness and swollen legs) and varicose veins prior to the 
symptoms of VTE in exposed and prior to the interview in unexposed. To monitor comorbidity, 
all women were asked about current and previous diseases including hyperlipidemia, 
hypertension, diabetes, stroke, acute myocardial infarction and angina pectoris. Women who 
conﬁrmed being affected by any of these conditions were considered as having that disease. 
Information on the location of the VTE was obtained through a copy of the radiology report. 
Genotyping 
Genotyping was performed using the Illumina GoldenGate platform and read and analyzed 
using the Illumina BeadXpress and Illumina GenomStudio 2011.1 software at the SNP&SEQ 
Technology Platform, Uppsala Sweden. SNPs in F5rs6025 and F2 rs1799963 were genotyped 
by Pyrosequencing technology (ISO standard 2004) at the Royal Institute of Technology, 
Stockholm (108). Genotyping was performed on plates containing both cases and controls and 
were completed in one stage for the Illumina platforms.  
4.2.2 TEHS-follow-up 
Information on the outcomes in TEHS-follow-up was obtained through the questionnaire and 
from Swedish Registers; the Patient Register, the Cause of Death Register and the Cancer 
Register.  
Recurrent VTE 
Information on recurrent disease was obtained both from the questionnaire as well as from the 
Patient Register. All possible recurrent events reported in the questionnaire or in the Patient 
Register were confirmed by a review of the medical record. To be considered a recurrent event 
it had to be radiological verified by the same methods as described in TEHS as well as be 
considered having indication for resumed anticoagulant treatment.   
Overall Mortality and Cardiovascular disease  
Information on time and causes of death for the deceased women were collected from the Cause 
of Death Register. Both primary and secondary causes of death were retrieved. The causes of 
death were classified into three groups; death by cardiovascular disease, malignancy or other 
cause. 
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The Patient Register was used to obtain information on CVD. Study endpoints in paper III were 
cardiovascular disease defined as myocardial infarction (ICD-10 code I20 and I25), ischemic 
stroke (ICD-10 code I63 and I64) or cardiovascular mortality (ICD-10 code I21, I25, I63, I46.1) 
and overall mortality.  
Health-related Quality of Life 
To assess generic QoL the questionnaire contained questions according to SF-36 (109, 110) 
The SF-36 consists of 36 items and assesses general wellbeing during the previous 30 days. It 
contains eight subscales: physical functioning, social functioning, physical role functioning, 
emotional role functioning, mental health, vitality, bodily pain and general health. Standard 
algorithms were used to calculate scores for the Mental Component Scale (mcs), a summary 
score that reflects scores on the vitality, social functioning, mental health, and emotional role 
scales, and the Physical Component Scale (pcs), a summary score that reflects scores on the 
physical functioning, physical role, bodily pain, and general health perceptions scales. Scores 
are expressed on a 0–100 scale, with higher values indicating better general wellbeing.   
To assess disease-specific QoL the questionnaire of the exposed women also included 
questions according to VEINES-QoL/VEINES-Sym (111).  The VEINES-QoL consists of 26 
questions that assess venous symptoms (heavy legs, aching legs, swelling, night cramps, heat 
or burning sensation, restless legs, throbbing, itching, tingling, intensity of leg pain), limitations 
in daily activities due to chronic venous disease, psychological impact of chronic venous 
disease, change over the past year, and time of day when the leg problem is most intense. The 
VEINES-Sym is a subscale of the VEINES-QoL that measures venous symptoms (111). 
Post-thrombotic syndrome 
PTS was evaluated in exposed women through a self-reported Villalta-scale (8) included in the 
questionnaire. To assess PTS there were questions asking for five symptoms and four signs 
(Table 2) for both lower limbs. Each item scored one point if present. The nine items were 
summed into a self-reported post-thrombotic score, where PTS was considered present if score 
≥ 4 points. For women with DVT the scores of the affected leg was used. For women with PE 
we used results from the leg with the higher score, assuming that they had a concomitant DVT 
in that leg.  
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Table 2 Self-reported  Villalta scale 
Symptoms Signs 
Spontaneous pain in calf Newly formed varicose veins 
Spontaneous pain on walking Swelling of foot or calf 
Spontaneous pain on standing Skin changes, pigmentation, discoloration 
Pain worsening during the day Skin changes with venous ulcers 
Heaviness of leg  
All symptoms and signs score 0 if absent and 1 if present. PTS was considered present if 
score ≥ 4.  
Adapted from Tick et al J Thromb Haemost 2008 
 
4.2.3 Swedish National Registers 
The National Board of Health and Welfare (Socialstyrelsen) hold a number of national 
registers. The registers were created for administrative purposes but researchers can apply for 
data needed for studies. It is mandatory by law for both public and private health care providers 
to report to the registers. 
Patient Register 
The National Patient Register started in 1967 when the National Board of Health and Welfare 
started to collect information regarding in-patients at public hospitals. In the beginning it 
covered 6 of the 26 county councils in Sweden but in 1984 it became mandatory for all county 
councils. From 1984 the Patient Register covers all in-patient care in Sweden. From 2001 it 
also includes all outpatient visits, including day-surgery, from private and public caregivers. 
Primary care is not covered in the Patient Register.  
The Patient Register contains information on age, sex, national registration number (a unique 
identification number assigned to each resident in Sweden) and main and secondary diagnosis 
for each patient visit or hospital admission. Diagnoses are recorded at each out-patient-clinic 
visit or at discharge from hospital according to the current International Classification of 
Diseases version 10 (ICD-10). The validity and coverage of the information included in the 
Patient Register is high, but varies across diagnoses (112-114). 
Cause of Death Register 
The Cause of Death Register contains data from 1961 and is updated annually. There are some 
historical data from 1952-1960, but the coverage may vary during that period. The Cause of 
Death Register covers all deaths occurring within or outside Sweden to individuals registered 
in Sweden as residents or citizens. The causes of death are coded centrally at Statistics Sweden 
according to ICD-10. The registry has high completeness regarding cause-specific death (115, 
116). 
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Cancer Register 
The Cancer Register was founded in 1958 and covers the whole population. Every health care 
provider must report newly diagnosed cancer, whether it is diagnosed clinical, morphological, 
on laboratory examination or at autopsy. Since the mid-80s the registration, coding and major 
check-up and correction work is performed at one of the six regional registries associated with 
the regional oncological centers in Sweden. The registry contains personal information (age, 
sex, national registration number) and medial data including information on the tumor site, 
histology, stage as well as date of diagnosis, basis of diagnosis and reporting hospital (117). 
The coverage of the register is high, a quality study in 2009 estimated the underreporting to be 
approximately 4 percent (118). 
4.3 STATISTICAL METHODS 
Baseline data in all four studies were compared using t-test to compare means for normally 
distributed, continuous data and Mann-Whitney U for non-normal, continuous or ordinal data. 
When comparing categorical data, we used chi2-test or, when appropriate, Fischer’s exact test. 
 
The Kaplan-Meier method was used to calculate cumulative recurrence rate in paper I-II and 
to calculate CVD and mortality in paper III. The difference between groups were compared 
using log-rank-test. In paper I alive patients were followed from end of anticoagulant treatment 
until recurrent event. Patients were censored at date of answering the questionnaire.  Paper II 
also included deceased women, calculating death as competing risk.  
Cox proportional hazard model was used to evaluate risk between groups in paper I-III. Both 
crude and adjusted hazard ratios (HR) with 95 % confidence intervals (95 % CI) were reported.   
Rate of recurrence in paper II and rate of CVD and mortality rate in paper III was calculated as 
number of events over the accumulated person-time.  
In paper IV analysis of variance (ANOVA) was used to calculate the difference between 
exposed and unexposed regarding QoL. ANOVA was also used to assess possible predictors 
of QoL among women with a previous episode of VTE. Separate analyses were made for SF-
36 pcs, mcs, VEINES-QoL and VEINES-Sym. 
To assess predictors of PTS in paper IV logistic regression was used, comparing women with 
PTS to women without PTS. Risks were calculated and reported as both crude and adjusted 
odds ratios (OR) and their corresponding 95 % CI. 
For all analyses p < 0.05 was considered statistically significant.  
Analyses of paper I, III and IV were performed using SPSS version 20-23 (SPSS Inc., Chicago, 
IL, USA). Analysis of paper II was performed using Stata version 13.  
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4.4 ETHICAL CONSIDERATIONS 
Both at time of inclusion in TEHS as well as in TEHS follow-up the study participants gave 
their written informed consent according to the Helsinki Declaration. All women were 
informed that they at any time could leave the study and have their data destroyed. Both TEHS 
and TEHS follow-up was approved by the regional research ethics committees in Stockholm 
(KI 01-255, 04-469), Uppsala (Ups 01-277), Linköping (01-453), Göteborg (M088-01), Umeå 
(01-198) and for TEHS-follow-up (EPN 2010/1200-31/1).  
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5 RESULTS 
5.1 PAPER I 
In paper I we studied the risk of recurrence after a first episode of VTE and in particular 
evaluated the risk in relation to whether the VTE was unprovoked, provoked by hormones or 
surgery/cast. 
We included all women (n=974) exposed to a previous VTE event (i.e. cases in TEHS) alive 
and accepting participation in TEHS-follow-up, and followed them for a median of 5.2 years 
(range 0.1-9.1 years) regarding recurrent events. At time of inclusion in TEHS the mean age 
was 49 years and 386 (40 %) of the participants were treated with hormones. During the follow-
up period 102 (10%) women had a recurrent event. For all women the recurrence rate was 
highest during the first year. Table 1 shows recurrence rate according to provoking factor at 
time of first VTE.   
 
Table 3. Cumulative incidence of recurrent VTE according to risk factor at first episode of 
VTE. 
	 All	women		
	
N=974	
Women	with		
Surgery/	Cast	
N=	350	
Women	with	
CHC/HT	
N	=272	
Women	with	
unprovoked	VTE	
N=	352	
1	year	 4%	 2%	 5%	 7%	
2	years	 6%	 3%	 7%	 10%	
3	years	 8%	 3%	 7%	 13%	
4	years	 9%	 3%	 8%	 15%	
5	years	 9%	 4%	 9%	 15%	
6	years	 11%	 6%	 10%	 18%	
CHC/HT	=	treatment	with	either	combined	hormonal	contraceptives	or	menopausal	hormone	
treatment.		
 
The risk of recurrence was lowest for women with a first VTE provoked by surgery/cast with 
a crude HR of 0.28 (95% CI 0.16-0.47) compared to women with unprovoked VTE. Women 
with hormonal provoked VTE had a lower recurrence rate (HR 0.57, 95% CI 0.39-0.90) 
compared to women with unprovoked VTE, but not as low as women with surgery/cast 
provoked VTE (Figure 4).  
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The risk of recurrence differed due to location of the initial VTE. Women with PE or proximal 
DVT had a higher risk of recurrence than women with distal DVT (HR 2.0, 95% CI 1.3-3.1). 
Women with obesity had an increased risk of recurrent VTE with a HR of 1.8 (95% CI 1.2-
2.7) compared to non-obese. The impact of obesity was largest among women below the age 
of 50. Age did not correlate with increased risk of recurrence.  
 
Figure 4. Cumulative incidence of recurrent VTE according to risk factor at first episode of 
VTE. 
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5.2 PAPER II 
In paper II the aim was to evaluate if seven genetic variants previously found to predict first 
time thrombosis in the study population of TEHS was associated with recurrence. The seven 
genetic predictors previously identified by Bruzelius et al (119) were F5 rs6025, F2 rs1799963, 
ABO rs514659, FGG rs2066865, F11 rs2289252, PROC rs1799810 and KNG1 rs710446. 
A total of 1010 women, of whom 38 deceased, were followed for a mean of 5 years. None of 
the deceased died from VTE.  During the total follow-up of 5094 person-years there were 101 
recurrent events.  
The genetic variables F5 rs6025 and F11 rs2289252 were significantly associated with 
recurrence in the genetic model, with HR 1.6 (95% CI 1.1-2.4) and 1.8 (95% CI 1.1-2.9) 
respectively, compared to women with no risk-allele.  
 
Table	4.	Multivariable	analysis	of	risk	factors	for	recurrent	VTE	in	a)	clinical,	b)	genetic	and	c)	
combined	model.	
	 HR	(a)	 [95	%	CI]	 HR	(b)	 [95	%	CI]	 HR	(c)	 [95	%	CI]	
Clinical	variables	 	 	 	 	 	 	
Proximal	DVT	vs	distal	DVT	 1.54	 [0.91–2.59]	 	 	 1.43	 [0.85–2.40]	
Pulmonary	embolism	vs	distal	DVT	 1.95	 [1.19–3.20]	 	 	 1.89	 [1.16–3.10]	
BMI	(kg/m2)	 	 	 	 	 	 	
25–29	vs	<	25	 1.39	 [0.85–2.27]	 	 	 1.41	 [0.87–2.30]	
30–	vs	<	25	 1.76	 [1.06–2.91]	 	 	 1.84	 [1.10–3.06]	
Provoked	VTE*	 	 	 	 	 	 	
Hormonal	use†	vs	Surgery	and/	or	cast	 1.96	 [1.05–3.64]	 	 	 1.89	 [1.02–3.54]	
None	vs	Surgery	and/or	cast	 2.98	 [1.72–5.18]	 	 	 2.89	 [1.66–5.04]	
Family	history	of	VTE	 	 	 	 	 	 	
Yes	vs	None	 1.4	 [0.93–2.11]	 	 	 1.33	 [0.88–2.00]	
Genetic	variables	 	 	 	 	 	 	
F5	rs6025	GA/AA	vs	GG	 	 	 1.65	 [1.09–2.50]	 1.57	 [1.02–2.41]	
F11	rs2289252	CT/TT	vs	CC	 	 	 1.8	 [1.09–2.96]	 1.59	 [0.96–2.62]	
N	 998	 	 1004	 	 992	 	
* within three month from diagnosis of first venous thrombosis; † combined contraceptives (oral, 
patch, vaginal devices) or oestrogen containing menopausal replacement therapy (oral and patch) 
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In carriers of both F5 rs6025 and F11 rs2289252 the cumulative recurrence rate was 2.5-fold 
higher compared to non-carriers (14.6% (95% CI 9.9-21.3%) vs 5.9% (95% CI 3.4-10.3%)) at 
5 years follow-up (Figure 5). This difference was even larger in the subgroup analysis of 
women with unprovoked VTE, 21.9% (95% CI 13.7-34.0%) vs 7.5% (95% CI 3.2-16%) 
(Figure 6). Both Kaplan-Meier curves were statistically different using the log-rank test.   
 
Figure 5. Cumulative recurrence comparing carriers of both risk alleles versus non-carriers 
of F5 rs6025 and F11 rs2289252. 
 
 
Figure 6. Sub-group analysis of women with unprovoked VTE. Cumulative recurrence 
comparing carriers of both risk alleles versus non-carriers of F5 rs6025 and F11 rs2289252. 
 
Carriers
Non-Carriers
Carriers
Non-Carriers
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5.3 PAPER III 
The objective of paper III was to evaluate the risk of overall mortality and CVD after a first 
episode of VTE compared to a control population.  
In the analysis we included 1081 women exposed to previous VTE and 1027 unexposed 
women, all with no CVD-event prior to inclusion in TEHS. During the total follow-up of 
11,920 person years 49 women suffered from any CVD event, 35 (3.2%, 95% CI 2.1-4.3) 
among the exposed and 14 (1.4%, 95% CI 0.7-2.1) among the unexposed (Figure 7).  
 
 
Figure 7. Cumulative incidence of cardiovascular disease. 
In a Cox proportional hazards model the crude HR for any CVD event was 2.2 (95% CI 1.2-
4.2) comparing exposed to unexposed. The risk of CVD was highest for women with 
unprovoked VTE and PE. In a multivariate model adjusting for age, BMI, hypertension and 
smoking the estimates were only slightly affected. 
The mortality rate in exposed women were 5.7 per 1000 person years and 2.2 per 1000 person 
years in unexposed generating a HR of 2.4 (95% CI 1.2-4.6). None of the women with known 
cause of death (n=45 out of 49) died from VTE. In both exposed and unexposed the major 
cause of death was malignancy (Table 5). 
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Table 5. Cause of death. 
	 Unprovoked	VTE	
N=22	
Provoked	VTE	
N=15		
Unexposed	
N=12	
	 n	 %	 n	 %	 n	 %	
Malignancy	 10		 45	 4		 27	 6		 50	
Cardiovascular	disease	 6		 27	 4		 27	 3		 25	
Miscellaneous	 5		 23	 5		 33	 2		 17	
Unknown	 1		 5	 2		 13	 1		 8	
 
When analyzing women with provoked and unprovoked VTE separately the mortality rate 
differed between women with unprovoked VTE compared to both unexposed women and 
women with provoked VTE (Figure 8). Log rank test showed statistical significance difference 
between the Kaplan-Meier curve of women with unprovoked VTE compared to the other two 
curves.  
 
Figure 8. Mortality among women with unprovoked VTE, provoked VTE and unexposed to 
VTE.  
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5.4 PAPER IV 
In study IV we evaluated QoL after a first episode of VTE in 1040 women compared to 994 
women with no previous VTE. Among exposed women we studied the prevalence of and risk 
factors for PTS. 
After a median follow-up of 6 years from first VTE-event in exposed women and 5.5 years 
from inclusion in TEHS for unexposed there were no clinically significant difference in QoL 
between the groups, measured with SF-36. However, women developing PTS during follow-
up had markedly impaired QoL compared to both unexposed women and women without PTS.  
In exposed women PTS was the predominant predictor of QoL measured with all four QoL-
instruments, SF-36 pcs, SF-36 mcs, VEINES-QoL and VEINES-Sym. Other predictors of low 
QoL measured with SF-36 were age, obesity and overweight, recurrent VTE and physical 
inactivity. VEINES-QoL and VEINES-Sym were only affected by PTS. Location of the initial 
thrombosis and whether it was provoked or unprovoked had no impact on QoL (Table 6).  
 
Table 6. Predictors of QoL in exposed women, multivariate. 
QoL-measure Variable* Parameter 
estimate 
p-value 
SF -36 pcs PTS  -8.6 < 0.001 
 Age > 50 -4.6 < 0.001 
 Recurrent VTE -4.4 < 0.001 
 BMI > 30 vs < 25 -6.6 < 0.001 
 BMI 25-30 vs  <25 -3.4 < 0.001 
 Physically inactive  -4.4 0.001 
 Low education  -2.7 0.002 
 Single -1.9 0.01 
SF-36 mcs PTS -4.9 < 0.001 
 Age > 50 +2.1 0.008 
 Single  -3.5 < 0.001 
 Recurrent VTE -3.1 < 0.001 
 Physically inactive  -3.0 0.001 
 Smoking -2.1 0.03 
 Low education  -2.3 0.03 
Veins-QoL PTS  -8.4 < 0.001 
 BMI > 30 vs < 25 -0.9 < 0.001 
 BMI 25-30 vs  <25 -0.8 0.01 
 Age > 50 -1.4 < 0.001 
VEINES-Sym PTS  -10.6 < 0.001 
 BMI > 30 vs < 25 -2.0 < 0.001 
 BMI 25-30 vs  <25 -0.9 0.01 
 Age > 50 -1.4 < 0.001 
* Variables included in the model: PTS, age, recurrent VTE, BMI, physical activity, 
education, civil status, smoking, provoked vs unprovoked VTE and location of VTE 
(PE, proximal DVT, distal DVT) 
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Twenty per cent of women with a previous VTE had self-reported Villalta-score above 3 points 
at time of follow-up. Women with proximal DVT had the highest prevalence of PTS (n=98, 
30%), followed by women with distal DVT (n=77, 19%) and women with PE (n=32, 11%). 
Obesity, proximal DVT, ipsilateral recurrence and presence of leg symptoms before first VTE 
were associated with an increased risk of PTS in a multivariate logistic regression model (Table 
7). 
Table 7. Risk factors associated with post-thrombotic syndrome in 1037 women after a first 
episode of VTE, presented as odds ratio (OR) and 95% Confidence Intervals (95%CI). 
	 Crude		 Adjusted	
	 OR	(95%	CI)	 OR	(95%	CI)	
Distal	DVT		 ref	 ref	
	 Prox.	DVT	 1.8	(1.3	–	2.6)	 1.7	(1.2	–	2.7)	
	 PE	 0.7	(0.5	–	1.0)	 0.6	(0.4	–	0.9)	
Unprovoked		 ref	 ref	
	 Surgery/	cast	 0.7	(0.4	–	1.0)	 0.7	(0.5	–	1.1)	
	 Hormonal	use*	 0,9	(0.7	–	1.5)	 1.4	(0.9	–	2.1)	
BMI	≥	30	 1.9	(1.3	–	2.6)	 1.7	(1.2	–	2.6)	
Leg	symptoms	 3.1	(2.3	–	4.4)	 3.1	(2.2	–	4.3)	
Recurrent	VTE	 1.7	(1.1–	2.8)	 1.4	(0.8	–	2.4)	
Ipsilateral	recurrence	 4.1	(2.0	–	8.4)	 2.9	(1.2	-	6.)	
Physical	activity	 1.2	(0.7	–	2.1)	 1.0	(0.5	–	1.8)	
*treatment	with	either	combined	hormonal	contraceptives	or	menopausal	
hormone	treatment.	
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6 DISCUSSION 
In these studies, on a nation-wide well-defined cohort of female patients with VTE, and a 
matched control population, we were able to evaluate risk factors for recurrent VTE as well as 
late complications as CVD and mortality and to assess QoL. The major strength of this thesis 
includes the large, well-defined, homogenous cohort, with detailed information on life-style 
factors, events taking place prior to VTE and socioeconomic factors, limited loss-to-follow-up 
and the prospective design. TEHS was a population-based study with standardized and detailed 
data collection through interviews, giving possibility to assess several risk factors at the same 
time. Information on the outcomes were collected both through questionnaires and Swedish 
National Registers. A weakness is the relatively low number of outcome events in study I-III 
giving rise to loss in statistical power and unable subgroup analysis.  
6.1 METHODOLOGICAL CONSIDERATIONS 
In observational studies both random and systematic errors can occur affecting precision, 
internal validity and generalizability of the study. These possible errors must be considered 
through-out the research process from designing the study, to finally interpreting the results.  
TEHS and TEHS follow-up did not include men, children and the elderly and therefore the 
results cannot be generalized to the whole population. The population-based design of TEHS 
with 43 including hospitals spread geographically in Sweden makes the external validity good 
for young and middle-aged women if the internal validity is good.  
6.1.1 Random error 
Even though the study population is large some of the outcomes studied are rare giving rise to 
loss in statistical power. In all papers estimates are presented with their 95 % CIs demonstrating 
the precision. In general, we have good statistical power for the variables studied. However, in 
some analysis, especially in subgroup analyses, the CIs are wide, demonstrating statistical 
uncertainty.         
6.1.2 Systematic error – selection bias 
Selection bias might occur if the association of exposure and outcome differs in those 
participating and not participating in the study. In this thesis selection bias might have occurred 
at different stages. First, when the cohort was recruited in TEHS, the participation rate was 
lower among controls compared to cases. Selection bias can occur if controls participating in 
the study to a higher degree had a medical history and therefore were more prone to participate.  
Secondly the loss to follow-up in TEHS-follow-up might give rise to selection bias. A total of 
25% refrained from participating in the follow-up. Selection bias can occur when loss to 
follow-up is associated with either the exposure or the outcome. In TEHS-follow-up the 
proportion of non-participants was almost similar among exposed and unexposed. When 
comparing the original cohort of TEHS to the cohort of TEHS-follow-up, women lost to 
follow-up were younger and more often smokers both among exposed and unexposed. The 
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only difference noted was that among exposed women there were a higher proportion of 
married women among those attending TEHS follow-up while there was no difference among 
unexposed (Table 8). Since the baseline characteristics between women attending TEHS-
follow-up and women lost-to-follow-up does not differ between exposed and unexposed the 
main effect of loss to follow-up should be loss in statistical power.  
Table 8 Baseline characteristics of the study cohort of TEHS-follow-up and the study 
participants from TEHS lost to follow-up. 
	 Exposed	 Unexposed	
	 TEHS-	
follow-up	
Lost-to	
follow-up	
TEHS	
follow-up	
Lost-to-
follow-up	
	
	 n	 %	 n	 %	 n	 %	 n	 %	
Age	(mean,	years)	 47	 	 44	 	 48	 	 44	 	
BMI	(mean,	kg/m2)	 27	 	 27	 	 25	 	 25	 	
	 BMI	<	25	 447		 41	 150		 43	 601		 59	 204		 54	
	 BMI	25-30		 370		 34	 114		 32	 300		 29	 116		 31	
	 BMI	>	30		 263		 24	 88		 25	 120		 12	 57		 15	
FV	Leiden	 252		 24	 57		 18	 76		 7.7	 32		 9.7	
FII	GA20210A	 56		 5.5	 19		 5.8	 29		 3	 8		 2.5	
Current	smoker	 267		 25	 110		 31	 197		 19	 108	 28	
Hypertension	 231		 21	 74		 21	 204		 20	 82		 21	
Diabetes	mellitus	 44		 4	 17	 5	 25		 2.5	 13		 3.4	
Married/cohabitant	 785		 73	 238		 68	 789		 78	 292	 77	
Physical	activity	 	 	 	 	 	 	 	 	
	 No	 80		 7	 27		 8	 34		 3	 17	 5	
	 Light	 422		 40	 158		 46	 355		 35	 129		 35	
	 Regular	 576		 53	 161	 71	 633		 62	 222		 61	
Education	 	 	 	 	 	 	 	 	
	 <	10	years	 178	 17	 59		 17	 125		 13	 51		 14	
	 10-12	years	 354	 34	 135		 39	 315		 32	 129		 35	
	 >	12	years	 505		 49	 151		 44	 542		 55	 194		 52	
Leg	symptoms	 400		 37	 142		 40	 286		 28	 104		 27	
Pulmonary	Embolism	 311		 29	 122		 35	 	 	 	 	
Deep	Vein	Thrombosis	 	 	 	 	 	 	 	 	
	 Proximal	 288		 27	 73		 21	 	 	 	 	
	 Distal	 479		 44	 158		 45	 	 	 	 	
Unprovoked	VTE	 413		 39	 142		 41	 	 	 	 	
Provoked	VTE*	 	 	 	 	 	 	 	 	
	 Surgery/cast	 366		 34	 117		 34	 	 	 	 	
	 Hormonal	use†	 292		 27	 83		 24	 	 	 	 	
* within three month from diagnosis of first venous thrombosis; † combined contraceptives (oral, 
patch, vaginal devices) or oestrogen containing menopausal replacement therapy (oral and patch)	
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Thirdly selection bias might have occurred when selecting the study populations in the different 
studies. In paper I and II all women with continuous anticoagulation were not included as they 
were considered not being at risk of recurrent events. Possible consequences of this will be 
discussed further under each paper.  
6.1.3 Systematic error – information bias 
Information bias or misclassification can occur when information on outcome or exposure is 
obtained differently in the different study groups. Misclassification may be either differential, 
if the probability of being misclassified differs between the study groups or non-differential. 
The result of non-differential misclassification is a dilution of the effect, bias towards the null, 
while differential misclassification might exaggerate or underestimate the effect.  
Misclassification of exposure in TEHS-follow-up 
The prospective study design with collection of information on VTE before the development 
of the outcome has minimized information bias due to recall bias. Misclassification of VTE is 
unlikely since the diagnosis was based on both radiological report as well as clinical decision 
to start anticoagulant treatment. The validity of diagnosing DVT with Doppler ultrasonography 
and phlebography and PE with CT scan or ventilation-perfusion scintigraphy together with 
high clinical suspicion of PE is high. During follow-up some of the women included as controls 
in TEHS, and therefore considered unexposed might have been diagnosed with VTE, hence 
being misclassified. Although since the incidence of VTE is about 1 to 2 per 1000 persons each 
year the expected number of misclassified unexposed women were low. To avoid immortal 
time bias, all controls of TEHS were included as unexposed in TEHS follow-up.   
Misclassification of outcomes in TEHS-follow-up 
The outcomes in TEHS follow-up were collected through self-reported information in the 
questionnaire as well as through register data minimizing misclassification. When answering 
the questionnaire, it was not apparent to the women what associations to be studied. In study I 
and II Information on recurrent events were based on data both in the questionnaire as well as 
data from the Patient Register. All possible recurrent events recorded either in the Patient 
Register or in the questionnaire were verified by reviewing medical charts minimizing recall 
bias and misclassification. In order to minimize surveillance bias in paper III only hard 
endpoints with clear diagnostic definitions, like myocardial infarction (MI) and ischemic 
stroke, were used. Information on PTS in paper IV was based on self-reported, modified, 
Villalta scale instead of Villalta scale evaluated and diagnosed by a physician. This may lead 
to misclassification bias discussed more in detail further on.  
6.1.4 Systematic error – confounding 
Confounding means that the effect of the exposure is mixed with the effect of another factor, 
leading to bias. To be a confounding factor the factor has to be associated with both the 
exposure and the outcome but not be an intermediate step in the causal pathway between 
exposure and outcome. There are three ways to prevent confounding while planning the study: 
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randomization, matching and restricting. Once the data is collected confounding can be 
controlled for by multivariable regression analysis. In the original recruitment to TEHS, the 
controls were matched to cases by age. In TEHS follow-up the age-matching disappeared due 
to loss-of-follow-up. However, the skewed age distribution was taken care of when analyzing 
the data, by adjusting for age. TEHS was restricted to women aged 18-64.  
In the analysis of all four studies we have been able to adjust for potential confounding factors. 
This was possible as we collected detailed information about the study participants during the 
interview of TEHS as well as in the questionnaire of TEHS-follow-up. There is a potential risk 
of recall-bias as well as interviewer bias for confounding factors collected at time of inclusion 
in TEHS. Information on exposures in TEHS, i.e. potential confounders in TEHS-follow-up, 
were collected retrospectively and recall bias might occur if women with VTE remember 
exposures better. Interviewer bias can occur if the interviewer is aware of the association 
between exposure, confounder and outcome and thereby asks the questions differently to 
exposed and unexposed. To minimize the risk of bias the interview was made by a trained 
nurse, aware of this problem. The interviewer used a structured questionnaire including a 
catalogue with pictures of different contraceptives and a life time calendar sent to the women 
to complete before the interview. To further diminish the risk of recall bias, the interview 
focused on the three-month period prior to the index event. In study III most confounding 
factors are life-style factors that may change over time. We measured life-style factors both at 
inclusion in TEHS as well as at time of follow-up. A sensitivity analysis was made adjusting 
for the same confounding factors measured at time of follow-up instead of inclusion in TEHS 
without any major changes in the risk estimates.  
6.2 MAIN FINDINGS 
6.2.1 Recurrent VTE (I and II) 
It is an important clinical challenge to evaluate the risk of recurrence in a patient with VTE and 
thereby safely be able to withhold anticoagulant treatment to patients with low risk of 
recurrence. For patients with unprovoked VTE there is a need for more precise prediction 
models. In none of the available models, HER DOO2, Vienna Prediction Model or DASH, 
screening for thrombophilia added any predictive value (45-47).  
In TEHS-follow-up the overall risk of recurrence for all women were low, with an annual 
incidence rate of about 2 %. Obesity, having an unprovoked VTE and the location of the 
primary VTE were the strongest clinical risk factors for recurrent events. The risk of recurrence 
for women with hormone-associated VTE were lower than for women with unprovoked VTE 
but not as low as for women with surgery/cast provoked VTE. Data concerning the risk of 
recurrence after hormone associated VTE are scarce. Many of previous studies are small 
cohorts or subgroup analysis reporting lower risk of recurrence in hormone users compared to 
unprovoked VTE, albeit not statistically significant (42, 43). There are not many studies 
including provoked VTE as well, and none is comparing hormone-associated VTE to 
surgery/cast associated VTE (39, 120). The results of TEHS follow up are in line with a cohort 
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study by Eischer et al in 2014, including only women with a first episode of unprovoked or 
hormone-associated VTE (121). 
The findings of a low risk of recurrence in women with hormone-associated VTE strongly 
suggest that long-term anticoagulant treatment safely can be withheld in this group of patients, 
as in patients with surgery/cast associated VTE. Nevertheless, women with unprovoked VTE 
had a higher risk of recurrence, especially in the first year after cessation of anticoagulant 
treatment, indicating the need for an instrument to divide these women into high and low risk 
of recurrence.   
In paper II we evaluated whether a genetic risk score, previously used in the same population 
to predict first episode of VTE (119), could be used to better predict recurrence. We found that 
F11 rs2289252 doubled the risk of recurrence, which was higher than for both F5 rs6025 and 
known family history. The association of F11 rs2289252 and first time VTE has been reported 
previously and has partly been explained by increased levels of FIX (122-124). There are 
growing evidence that FIX may be a key player in the pathogenesis of thromboembolic disease 
(125, 126). The risk of recurrence was 2.5 times higher at 5 years follow-up for carriers of both 
F5 rs6025 and F11 rs2289252 than non-carriers. In the sub-group analysis of patients with 
unprovoked VTE this difference was even more pronounced. The risk of recurrence in women 
carrying both F5 rs6025 and F11 rs2289252 were slightly higher than for women carrying ≥ 5 
of the 7 SNPs predicting first time VTE. Considering this, using the sum of genetic variants 
like in the MEGA follow-up (127) might underestimate the risk in patient with few risk alleles, 
albeit the alleles being high risk variants. Our results in paper II indicate that a combination of 
common genetic variant may be useful to predict risk of recurrence in women, especially after 
an episode of unprovoked VTE.  
The strength of paper I and II is the well-defined cohort of a homogenous population. The use 
of both the questionnaire and the Patient Register to obtain recurrent events as well as verifying 
them by reviewing the medical charts reassured that all events were identified and clinically 
relevant. Hence, when interpreting the data a few limitations has to be taken into account. 
Patients with ongoing anticoagulant treatment were excluded as they were not considered being 
at risk of recurrence. Therefore, patients considered having high risk of recurrence already at 
time of first VTE, and thereby prescribed indefinite anticoagulation, were not included in our 
study. The low number of recurrent event left us with reduced statistical power.  
6.2.2 Cardiovascular disease (III) 
Growing evidence during the recent years have suggested that there might be a potential link 
between venous and arterial thrombosis. It is still unclear though whether this link is real or 
due to bias, chance or confounding.  
In paper III we evaluated the risk of arterial CVD in 1081women with a first episode of VTE 
compared to 1027 women with no prior VTE. We found a 2-fold increased risk of CVD in 
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exposed women. The estimates were only modestly changed when adjusting for cardiovascular 
risk factors suggesting common risk factors is not the full explanation.  
According to Lijfering et al (66) there might be three possible options how VTE and CVD are 
relate, illustrated by the directed acyclic graphs (DAGs) in figure 9.  
 
Figure 9. Directed acyclic graphs illustrating three hypotheses of how venous and arterial 
thrombosis may be associated. Lijfering VM et al Seminars in thrombosis and hemostasis 2011. 
Figure is reused and modified with the kind permission of dr Lijfering.  
The two diseases might be associated through arteriosclerosis (Figure 9, 1b) though 
arteriosclerosis enhances inflammation and coagulation. The association might also be causal 
(Figure 9, 2 a-c). One possible explanation might be that arterial thrombosis is caused by the 
inflammatory process initiated by the venous thrombus. This explanation would explain why 
some studies found an increased risk of CVD during the first year after VTE (60, 69). Another 
explanation may be that treatment with vitamin K antagonists lead to increased arterial 
calcification. The association might also be explained by confounding by common risk factors 
for both diseases (Figure 9, 1 b and 3a). Then, adjusting for risk factors for CVD would lead to 
a decreased relative risk. Increased age and obesity are the only robustly reported common risk 
factors for VTE and CVD (66, 128). 
 In TEHS-follow-up the risk of CVD was unchanged after adjustment for measured 
cardiovascular risk factors at baseline. However, cardiovascular risk factors might change over 
time. To overcome this, we performed a sensitivity analyses adjusting for the same factors at 
time of follow-up instead, with no major change in risk estimates. Nevertheless, there might 
still be residual confounding due to unknown or unmeasured confounding factors, for instance 
genetic factors. In TEHS, we previously found that the only shared genetic risk factor, among 
common genetic variants associated with CVD, was the ABO locus (129) In TEHS follow-up 
the risk of CVD between exposed and unexposed started to diverge after one year (Figure 8) 
and the Kaplan Meier curves were parallel thereafter which might support that the VTE event 
itself or the treatment therefore may have a causal effect of CVD. 
VTAS
RF
VT
AS AT
1a) direct causal
1b) confounding between  
AT and VT
AS ATVT
VT AS ATRF
ATVT 2a) direct causal
2b) indirect causal
2c) indirect causal
VT
RF AS AT 3a) confounding between  
VT and AS and 
between VT and AT
AS, atherosclerosis; AT, arterial thrombosis; RF, risk factors; VT, venous thrombosis. 
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Strengths of this study include the use of hard endpoints obtained by the Swedish National 
Registers with high coverage and validity of the defined diagnoses reducing misclassification. 
By collecting detailed information on cardiovascular risk factor both at time of inclusion in 
TEHS and TEHS follow-up it was possible to adjust for potential confounding factors. The 
limitations that one should bare in mind interpreting the results are that there are few outcome 
events giving rise to statistical uncertainty. Unfortunately, the study design did not allow us to 
adjust for the effect of anticoagulant treatment or other pharmacological treatments.  
6.2.3 Mortality (III) 
Overall survival is affected by VTE, especially in patients with underlying malignancy. 
In TEHS only women with good life-expectancy were included, since women with malignant 
disease were not eligible and the prevalence of comorbidities were low. Hence, women exposed 
to VTE had a two-fold increased risk of overall mortality compared to unexposed women. 
None of the women with known cause of death (n=45/49) died from VTE. In ten of the thirteen 
women with cardiovascular death the cause of death was based on autopsy results. This reduced 
misclassification bias, due to PE-related death misdiagnosed as CVD. Overall, the mortality 
rate was low compared to previous studies on patients with VTE (32, 78). The difference may 
be explained by TEHS not including patients with known malignancy and being restricted to 
patients below 65 years of age. The mortality rate in the control population was comparable to 
the mortality rate reported by the National Board of Health and Welfare for the general 
population of women 18–64 years of age in Sweden (115). The elevated risk of mortality was 
seen in women with unprovoked VTE. Death due to malignancy was twice as common among 
exposed women compared to unexposed. In a stratified analysis of women with provoked and 
unprovoked VTE it is found that the elevated risk of cancer-associated mortality occurred 
among women with unprovoked VTE. This might reflect that unprovoked VTE not seldom is 
the first manifestation of cancer, not diagnosed at time of inclusion in TEHS.  
Among the strengths of this study are the long-term follow-up of a well-defined cohort. The 
use of National Registers with good validity to retrieve mortality data and a high proportion of 
women with cardiovascular deaths based on autopsy results minimized misclassification. A 
limitation of the study may be that the follow-up time for unexposed are shorter compared to 
exposed introducing selection bias. Restricting the analysis for the first two years may be a way 
to overcome this, however the low number of events did not allow us to do that without losing 
power.  
6.2.4 Quality-of-life (IV) 
The limited number of studies on QoL after VTE have found that the main predictor of QoL 
after VTE is occurrence of PTS.  
In paper IV we found that on average there were no difference in QoL in exposed and 
unexposed women. However, in consistence with previous studies (79, 88, 89), women 
developing self-reported PTS had markedly lower QoL compared to both unexposed women 
and exposed women without PTS. Age, obesity, inactivity and recurrent VTE also affected 
general physical health in our study. Having a proximal DVT did not affect QoL, as opposed 
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to a study by Kahn et al (10). Even though we have a larger number of study participants 
compared to the study by Kahn the proportion of patients with proximal DVT is lower. 
Although, we have 90 % power to detect a difference of 3 points in our study population, it 
might be that we missed significant associations of smaller magnitude. Since the study by Kahn 
et al included older patients as well as patients with malignancy the affection of QoL in patients 
with proximal DVT might be due to a higher incidence of comorbidities rather than the 
proximal location itself. We found no differences in age, BMI or prevalence of malignancy 
during follow-up between patients with proximal or distal DVT except that more women with 
distal DVT had a surgery/cast provoked DVT than women with proximal DVT.  
To our knowledge, only few studies have examined the effect of socioeconomic factors on QoL 
after VTE. Short education was an independent predictor of SF-36 pcs, while VEINES-QoL 
was only affected in the univariate model. A Norwegian study on women with pregnancy-
related VTE  has reported that low education was an independent risk predictor for VEINES-
QoL scores < 25th percentile as compared with the ≥50th percentile (130).  
Physically active women reported better QoL measured with SF-36 pcs. The results from 
previous studies on physical activity and QoL in VTE-patients are inconsistent. One 
randomized trial could not show any effect on QoL with physical activity, while two smaller 
studies report improved QoL by exercise (131-133).  
The major strengths of the study on QoL is the large population-based, homogenous cohort 
with detailed information on life-style factors and socioeconomic factors. QoL was 
comprehensively assessed by the use of both generic and disease specific QoL instruments. 
There are some limitations that one has to consider when interpreting the results. The loss to 
follow-up might have introduced selection bias. Women not accepting participation in the 
follow-up study are younger (mean age 44 vs. 47 years for exposed and 44 vs. 48 years for 
unexposed) and more often smokers (31% vs. 25% for exposed and 28% vs. 19% for 
unexposed) than participants. It should be noted though that the loss to follow-up was similar 
among exposed and unexposed women except slightly more married women among the 
exposed participating in the follow-up (73% vs. 68% for exposed and 78% vs. 77% for 
unexposed). 
6.2.5 Post-thrombotic syndrome (IV) 
PTS is the most common complication of VTE. In TEHS follow-up the prevalence of self-
reported PTS was 20% for the total cohort. Compared to other studies that is a low prevalence 
of PTS (8, 58, 134). One explanation may be the large proportion of women with distal DVT 
in our cohort. However, analyzing women with proximal DVT separately still reveals a low 
prevalence of PTS. Since age has been reported to affect PTS (8, 96, 135) the restriction of 
TEHS including only women below 65 years of age may explain the low occurrence of PTS. 
The prevalence of PTS may also be low due to high quality of anticoagulation therapy in 
Sweden (136, 137).  
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Our findings that obesity, proximal DVT and recurrent ipsilateral DVT increased the risk of 
PTS has been reported previously (8, 96, 97). Women in TEHS reporting leg symptoms like 
heaviness, pain and swollen legs prior to the onset of VTE-symptoms have a 3-fold increased 
risk of PTS. There is no gold standard test for PTS, hence the diagnosis is clinical (99). The 
recommended tool to use, the Villalta scale, comprises of 5 subjective symptoms and 6 
objective signs, neither being specific to PTS. The signs and symptoms reported could therefore 
be due to primary venous insufficiency (PVI) (134). It might be that women in TEHS reporting 
leg symptoms prior to VTE are misdiagnosed with PTS rather than PVI. It could also be that 
these women have PVI prior to VTE and that venous insufficiency plays a role in the 
occurrence of PTS. Previous findings from the REVERSE study and the MEGA study support 
this theory (134, 138).  
The size of the cohort and comprehensive information on life-style factors and leg symptoms 
prior to VTE are the major strengths of this study. There are however some limitations that has 
to be mentioned. We used a modified Villalta scale to assess PTS, not being validated in our 
setting. The same modified scale has however been used and validated in the MEGA study (8) 
with good correlation to the original Villalta scale (kappa 0.88, 95 % CI 0.79-0.96). A study 
from Norway validating a modified Villalta scale reported that patients usually overestimated 
their signs compared to professional health care givers. We did not use the Villalta scale to 
grade the severity of PTS but rather to assess whether women had developed PTS or not. The 
prevalence of PTS was rather low indicating that overestimation of PTS may not have been a 
problem. Another limitation that may introduce bias is loss to follow-up. The prevalence of PE 
as primary VTE was lower among women accepting participating in TEHS-follow-up than 
those lost to follow-up. Therefore, the prevalence of PTS in the whole cohort might be 
overestimated. However, a sensitivity analysis stratified by location of thrombosis showed no 
major difference in the risk estimates for the predictors of PTS.   
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7 CONCLUSION 
• The overall risk of recurrence in young and middle-aged women was low and in the 
majority of patients prolonged anticoagulation therapy can be safetly withheld. Women 
with hormone associated VTE had a lower risk of recurrence than women with 
unprovoked VTE but not as low as after surger/cast provoked VTE. 
 
• The risk of recurrence was for the first time found to be associated with the risk allell 
F11 rs 2289252. Especially among women with unprovoked VTE the combination of 
the F5 rs6025 and F11 rs2289252 contributed to the risk of recurrent VTE and might 
be of clinical relevance for risk prediction. 
 
• Compared to a control population women with previous VTE had an increased risk of 
future arterial cardiovascular disease and overall mortality. The risk was highest among 
women with uprovoked VTE and pulmonary embolism. The elevated risk of 
cardiovascular disease was only modestly changed after adjustment for cardiovascular 
risk factor suggesting there might be a causal effect.   
 
• About a fifth of women developed PTS as a chronic complication of VTE. Women 
with ipsilateral recurrence and reporting leg symptoms prior to VTE had the highest 
risk of PTS.Women developing PTS had severely impared health related QoL while 
QoL in women with VTE not developing PTS was similar compared to a control 
population.  
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8 FUTURE PERSPECTIVES 
The best way to avoid VTE complications in women is to prevent the first occurrence of VTE. 
The major risk factors for incident VTE in women in young and middle age is the use of 
estrogen containing hormones and surgery. Better ways to identify women at high risk of 
incident VTE is warranted to be able to prescribe hormones safer and more frequent use, or 
prolong, thromboprophylaxis among these women.  
In the future there is a need for a better understanding of the epidemiology and risk factors for 
recurrent VTE. For patients it is important to have a good, validated tool to be able to balance 
the risk of major bleeding with continues anticoagulant treatment against the risk of recurrence 
after stopping anticoagulation. Since women are found to have a lower risk of recurrence than 
men there might be a need for a separate risk score for women.  
Obesity is a risk factor not only for primary VTE but also for recurrence, PTS and lower QoL. 
The mechanism how obesity predisposes VTE is however not fully understood. Studies on the 
influence of weight-loss on risk of VTE, recurrence, PTS and QoL would be interesting to learn 
more of the mechanism of obesity and VTE and in a better way tailor preventive actions.  
There is a need for a better understanding of the relation between venous and arterial 
thrombosis. Hence, if the relationship is causal than every VTE patient might benefit from 
arterial thrombosis prevention while only patients with cardiovascular risk factors should be 
directed if the association is due to common risk factors. The findings that statins and low-dose 
aspirin might protect against recurrent VTE is interesting and deserves further studies.  
There is a need for a better PTS risk prediction tool including both clinical and biomarker 
information. Since inflammation might be a part of the development of PTS it would be 
interesting to study the influence on anti-inflammatory agents, prolonged treatment with 
LMWH and the influence on treatment with NOACs on the risk of PTS.    
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9 SAMMANFATTNING PÅ SVENSKA  
Bakgrund 
Venös trombos är ett samlingsnamn för blodproppar i kroppens vener. De vanligaste 
lokalisationerna för venös trombos är i benen eller i lungan. Venös trombos är en vanlig och 
potentiellt livshotande sjukdom som årligen drabbar 1-2 per 1000 personer. Venös trombos 
förekommer hos både män och kvinnor, men kvinnor drabbas oftare i yngre ålder delvis 
beroende av behandling med  p-piller och graviditet. Även östrogenbehandling i klimakteriet 
ökar risken för venös trombos.  
Efter ett första insjuknande i venös trombos finns risk för återfall i sjukdomen. Den risken kan 
minimeras genom att äta blodförtunnande läkemedel, en behandling som dock innebär en ökad 
risk för allvarlig blödning. Det är därför viktigt att kunna bedöma risken för återfall, för att 
kunna hitta de patienter som har låg risk att drabbas av återfall och därmed säkert kan avstå 
från långtidsbehandling med blodförtunnande läkemedel. Risken för återfall är lägre hos 
kvinnor än män, orsaken till det är inte helt klarlagd. Efter en venös trombos kommer ett flertal 
att drabbas av posttrombotiskt syndrom (PTS). PTS är ett kroniskt tillstånd med symtom i form 
av smärta, tyngdkänsla, svullnad, klåda och kramp i det drabbade benet. Bland de få studier 
som studerat livskvalitet efter en venös trombos ses att förekomst av PTS är det som har störst 
påverkan på livskvalitet efter en venös trombos. Andra långtidskomplikationer efter venös 
trombos verkar vara en ökad risk för hjärtkärlsjukdom och ökad dödlighet.  
Syfte 
Målet med avhandlingen är att få bättre kunskap om långtidskomplikationerna efter en venös 
trombos hos kvinnor mellan 18-64 år genom att studera: 
• Risken för återfall i venös trombos och studera om återfallsrisken skiljer sig för de 
kvinnor som haft en blodpropp utlöst av hormoner, kirurgi eller gips jämfört kvinnor 
med idiopatisk (utan känd orsak) trombos.  
• Om förekomst av vanliga genetiska förändringar kan användas för att hitta kvinnor med 
ökad risk för återfall i trombos.  
• Risken för hjärtkärlsjukdom och död hos kvinnor efter en venös trombos jämfört med 
risken hos kvinnor som inte haft venös trombos.  
• Livskvalitet efter en venös trombos jämfört med den hos kvinnor utan trombos samt 
studera förekomst av PTS efter en förstgångstrombos och hur det påverkar 
livskvaliteten.  
Metod 
Studierna i denna avhandling är gjorda på en grupp av kvinnor hämtade från en svensk studie, 
‘Thrombo-Embolism Homonal Study’ (TEHS). Avsikten med TEHS var att studera medfödda 
och förvärvade riskfaktorer för venös trombos hos kvinnor. Mellan 2002 och 2009 
inkluderades 1433 kvinnor med en förstagångs venös trombos och 1402 jämnåriga kvinnor 
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utan venös trombos. Kvinnor som hade eller haft cancer senaste 5 åren, tidigare 
trombossjukdom eller graviditet senaste 3 månaderna exkluderades från studien. 
Under 2011 tillfrågades alla kvinnor som deltog i TEHS och som levde i Sverige om deltagande 
i uppföljningsstudien, TEHS-follow-up. Kvinnorna tillfrågades skriftligt, genom att en enkät 
skickades till dem per brev. För de kvinnor som accepterade deltagande i TEHS-follow-up 
(1087 kvinnor med trombos och 1030 kvinnor utan trombos) och för de som avlidit under 
uppföljningsperioden (38 kvinnor med trombos och 12 kvinnor utan trombos) inhämtades data 
om hjärtkärlsjukdom och återfall även från svenska hälsoregister. Enkäten innehöll frågor för 
att mäta livskvalitet och förekomst av PTS.  
Resultat 
Studien visar att den sammanlagda risken för återfall i studiepopulationen är låg. Kvinnor med 
idiopatisk trombos och kvinnor med fetma har högst risk för återfall. Återfallsrisken för de 
kvinnor som drabbats av en hormonutlöst trombos är lägre än för kvinnor med idiopatisk 
trombos men inte lika låg som för kvinnor med trombos utlöst av kirurgi eller gips. Kvinnor 
med förekomst av 2 genetiska förändringarna (F5 rs6025 och F11 rs2289252) har ökad risk 
för återfall vilket talar för att kombinationen av dessa gener möjligen kan användas för att hitta 
de kvinnor som har ökad risk för återfall.  
Andelen kvinnor med venös trombos som drabbats av hjärtkärlsjukdom eller död under 
uppföljningstiden var låg, men jämfört med kvinnor utan trombos var risken fördubblad.  
Omkring en femtedel av kvinnorna hade utvecklat PTS under uppföljningstiden. Dessa kvinnor 
hade en tydligt sänkt livskvalitet. För kvinnor med trombos utan PTS skiljde sig inte 
livskvaliteten jämfört de kvinnor som inte haft trombos.  
Slutsats 
Sammanfattningsvis har denna avhandling bidragit till att öka kunskapen om 
långtidskomplikationer efter venös trombos hos unga och medelålders kvinnor. Efter en venös 
trombos är den vanligaste komplikationen PTS, ett kroniskt tillstånd med påverkan på framtida 
livskvalitet. För majoriteten av kvinnor är risken för återfall i trombossjukdom låg och 
långtidsbehandling med blodförtunnande medicin är inte motiverat.  
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